aspirin has been researched along with Fatty Liver in 20 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet." | 5.37 | Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011) |
| "Acute fatty liver is a rare but fatal complication of pregnancy." | 5.32 | Acute fatty liver of pregnancy after aspirin intake. ( Deren, O; Durukan, T; Kizilkiliç-Parlakgümüş, A; Onderoğlu, L; Saygan-Karamürsel, B, 2004) |
| "This cohort study demonstrated that regular aspirin use was associated with a reduced risk of liver disease in men without an elevated risk of gastrointestinal bleeding or ulcers." | 4.31 | Aspirin is associated with a reduced incidence of liver disease in men. ( Alqahtani, S; Creasy, KT; Hehl, L; Krishnan, A; Rader, DJ; Rendel, MD; Schneider, CV; Schneider, KM; Scorletti, E; Seeling, KS; Serper, M; Trautwein, C; Vell, MS; Vujkovic, M; Wangensteen, K; Zandvakili, I, 2023) |
| "All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group." | 3.74 | Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. ( Abe, Y; Endo, H; Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Kobayashi, N; Kubota, K; Nagashima, Y; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Wada, K; Yoneda, M, 2008) |
| "Effects of inhibitors of arachidonic acid (AA) metabolism on the development of fatty liver, cirrhosis, glutathione-S-transferase placental form (GST-P)-positive nodules and the generation of 8-hydroxydeoxyguanosine (8-OHdG) and thiobarbituric acid-reactive substances (TBARS), caused by a choline-deficient, L-amino acid-defined (CDAA) diet, were examined in male Fischer 344 rats by feeding CDAA diets supplemented with the inhibitors for 12 and 30 weeks." | 3.69 | Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. ( Denda, A; Endoh, T; Horiguchi, K; Kobayashi, E; Konishi, Y; Nakae, D; Noguchi, O; Ogasawara, H; Sugimura, M; Tamura, K; Tang, Q; Tsujiuchi, T, 1996) |
| "Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide." | 1.56 | Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. ( Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet." | 1.37 | Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011) |
| "Aspirin intake was associated with reduced risk for sinusoidal lesions (P = ." | 1.35 | Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. ( Beauchet, A; Benoist, S; Brouquet, A; Julie, C; Nordlinger, B; Penna, C; Rougier, P, 2009) |
| "Acute fatty liver is a rare but fatal complication of pregnancy." | 1.32 | Acute fatty liver of pregnancy after aspirin intake. ( Deren, O; Durukan, T; Kizilkiliç-Parlakgümüş, A; Onderoğlu, L; Saygan-Karamürsel, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (45.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vell, MS | 1 |
| Krishnan, A | 1 |
| Wangensteen, K | 1 |
| Serper, M | 1 |
| Seeling, KS | 1 |
| Hehl, L | 1 |
| Rendel, MD | 1 |
| Zandvakili, I | 1 |
| Vujkovic, M | 1 |
| Scorletti, E | 1 |
| Creasy, KT | 1 |
| Trautwein, C | 1 |
| Rader, DJ | 1 |
| Alqahtani, S | 1 |
| Schneider, KM | 1 |
| Schneider, CV | 1 |
| Rosa, L | 1 |
| Lobos-González, L | 1 |
| Muñoz-Durango, N | 1 |
| García, P | 1 |
| Bizama, C | 1 |
| Gómez, N | 1 |
| González, X | 1 |
| Wichmann, IA | 1 |
| Saavedra, N | 1 |
| Guevara, F | 1 |
| Villegas, J | 1 |
| Arrese, M | 1 |
| Ferreccio, C | 1 |
| Kalergis, AM | 1 |
| Miquel, JF | 1 |
| Espinoza, JA | 1 |
| Roa, JC | 1 |
| Kinter, CW | 1 |
| Saxon, GE | 1 |
| Ahmad, M | 1 |
| Berhane, H | 1 |
| Gensler, L | 1 |
| Khosroshahi, A | 1 |
| Fujita, K | 1 |
| Nozaki, Y | 1 |
| Wada, K | 1 |
| Yoneda, M | 1 |
| Endo, H | 1 |
| Takahashi, H | 1 |
| Iwasaki, T | 1 |
| Inamori, M | 1 |
| Abe, Y | 1 |
| Kobayashi, N | 1 |
| Kirikoshi, H | 1 |
| Kubota, K | 1 |
| Saito, S | 1 |
| Nagashima, Y | 1 |
| Nakajima, A | 1 |
| Brouquet, A | 1 |
| Benoist, S | 1 |
| Julie, C | 1 |
| Penna, C | 1 |
| Beauchet, A | 1 |
| Rougier, P | 1 |
| Nordlinger, B | 1 |
| Ibrahim, M | 1 |
| Farghaly, E | 1 |
| Gomaa, W | 1 |
| Kelleni, M | 1 |
| Abdelrahman, AM | 1 |
| Russo, MW | 1 |
| Pierson, J | 1 |
| Narang, T | 1 |
| Montegudo, A | 1 |
| Eskind, L | 1 |
| Gulati, S | 1 |
| GILES, HM | 1 |
| Saygan-Karamürsel, B | 1 |
| Kizilkiliç-Parlakgümüş, A | 1 |
| Deren, O | 1 |
| Onderoğlu, L | 1 |
| Durukan, T | 1 |
| Farhadi, A | 1 |
| Gundlapalli, S | 1 |
| Shaikh, M | 1 |
| Frantzides, C | 1 |
| Harrell, L | 1 |
| Kwasny, MM | 1 |
| Keshavarzian, A | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Fraser, JL | 1 |
| Antonioli, DA | 1 |
| Chopra, S | 1 |
| Wang, HH | 1 |
| Endoh, T | 1 |
| Tang, Q | 1 |
| Denda, A | 1 |
| Noguchi, O | 1 |
| Kobayashi, E | 1 |
| Tamura, K | 1 |
| Horiguchi, K | 1 |
| Ogasawara, H | 1 |
| Tsujiuchi, T | 1 |
| Nakae, D | 1 |
| Sugimura, M | 1 |
| Konishi, Y | 1 |
| Linnemann, CC | 1 |
| Ueda, K | 1 |
| Hug, G | 1 |
| Schaeffer, A | 1 |
| Clark, A | 1 |
| Schiff, GM | 1 |
| Thaler, MM | 1 |
| Velásquez-Jones, L | 1 |
| Simell, O | 1 |
| Hilty, MD | 1 |
| Romshe, CA | 1 |
| Delamater, PV | 1 |
| Strauss, RG | 1 |
| McAdams, AJ | 1 |
1 review available for aspirin and Fatty Liver
| Article | Year |
|---|---|
Metabolic mechanisms in Reye syndrome. End of a Mystery?
Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Aspirin; Brain Diseases; Carbamoyl-Phosphate Synthase | 1976 |
19 other studies available for aspirin and Fatty Liver
| Article | Year |
|---|---|
Aspirin is associated with a reduced incidence of liver disease in men.
Topics: Aspirin; Cohort Studies; Fatty Liver; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Liver | 2023 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic D | 2020 |
Multisystem inflammatory syndrome in an adult with involvement of the skin, lymph nodes, muscle, heart, liver and kidneys.
Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Aspirin; Asymptomatic Infections; Biomarkers; | 2021 |
Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspirin; Cholesterol; Choline Deficiency; Cilostazol; Dietary Fats; D | 2008 |
Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.
Topics: Aged; Antineoplastic Agents; Aspirin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; | 2009 |
Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspirin; Cyclooxygenase 2; Fatty Liver; Gene Expression Regulation, E | 2011 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastroi | 2012 |
ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA.
Topics: Aspirin; Brain Diseases; Carbohydrate Metabolism; Coma; Fatty Liver; Heart Diseases; Humans; Kidney | 1965 |
Acute fatty liver of pregnancy after aspirin intake.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Component Transfusion; Diagnosis, Dif | 2004 |
Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endotoxemia; Fatty Liver; Female; Humans; I | 2008 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Prevalence and nonspecificity of microvesicular fatty change in the liver.
Topics: Aged; Aged, 80 and over; Aspirin; Fatty Liver; Female; Humans; Male; Middle Aged; Pilot Projects; Ri | 1995 |
Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.
Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver | 1996 |
Salicylate intoxication and influenza in ferrets.
Topics: Animals; Arginase; Argininosuccinate Lyase; Aspartate Aminotransferases; Aspirin; Carbamoyl-Phosphat | 1979 |
[Reye's syndrome and the administration of acetylsalicylic acid in children].
Topics: Aspirin; Child; Fatty Liver; Humans; Liver; Muscles; Reye Syndrome; Virus Diseases | 1985 |
[Reye's syndrome--visceral fatty degeneration and encephalopathy].
Topics: Aspirin; Brain; Child; Fatty Liver; Humans; Reye Syndrome; Virus Diseases | 1985 |
Reye's syndrome and hyperaminoacidemia.
Topics: Amino Acids; Aspirin; Brain Diseases; Child; Child, Preschool; Diagnosis, Differential; Fatty Liver; | 1974 |
Arthritis, aspirin, and coma.
Topics: Arthritis, Juvenile; Aspirin; Brain Edema; Chemical and Drug Induced Liver Injury; Child, Preschool; | 1970 |
Reye's syndrome and salicylate intoxication.
Topics: Adipose Tissue; Aspirin; Brain Diseases; Chemical and Drug Induced Liver Injury; Fatty Liver; Humans | 1970 |